Biopharma licensings, joint ventures and collaborations, including: 4SC, Abbvie, Amgen, Aska, Astellas, Astrazeneca, Bayer, Biogen, Biomed X, Boehringer, Chiesi Farmaceutici, Clinigen, Curis, Cyclica, Daewoong, Daiichi Sankyo, Evotec, Gilead, Hikma, Innovent, Inovio, Ionis, Iovance, Janssen, Mediwound, Merck & Co., Merck KGaA, Mundipharma, Nestle, Novartis, Novo Nordisk, Pfizer, Pharmamar, Phasebio, Probiogen, Roche, Schrodinger, Syndivia, Takeda.

The top 10 biopharma stock gainers and losers for the week.

The top 10 med-tech stock gainers and losers for the week.

A quick look back at top stories, including: Advaxis, Avrobio, Beam, Biohaven, Blue Water, CNS, Collegium, Cortexyme, Deciphera, Eli Lilly, Genprex, Gibson, I-Mab, Inato, Logicbio, Moderna, Personalis, Promedior, Revance, Revolution, Roche, Syros, Theravance, Xeris, WPD.

Total raised in public, private and other financings of biopharma companies, comparing 2020 vs. 2019.

Year-to-date money raised in public, private and other financings of biopharma companies.

Regulatory decisions affecting biopharma products in development, including: Abbvie, Aimmune, Alkermes, Alnylam, Amarin, Biohaven, Biolinerx, Blueberry, Clovis, Cytodyn, Durect, Emergent, Evoke, Exelixis, Fate, F-star, Galapagos, Genmab, Horizon, Incyte, Ipsen, Janssen, Jubilant, Mesoblast, Nabriva, Nektar, Nicox, Orion, Pharmacyte, Pharming, Pulmatrix, Recordati, Regeneron, Seelos, Sorrento, Ultragenyx, Vistagen.

The top 10 biopharma stock gainers and losers for the week.

The top 10 med-tech stock gainers and losers for the week.